IRDye® 800CW RGD Optical Probe

Integrins are cell surface heterodimeric glycoproteins involved in cell-to-cell and cell-to-matrix interactions[1]. The recognition motif, RGD (Arg-Gly-Asp), is a tripeptide sequence used to bind integrin receptors including αvβ3. Interest in using a labeled RGD peptide ligand for the study and/or monitoring of diseases related to the αvβ3 receptor over-expression is increasing. Several groups have labeled RGD successfully with fluorescent dyes for in vitro and in vivo imaging[2,3].

Characterization of IRDye 800CW RGD included in vitro and in vivo binding to a variety of tumor cell lines (i.e., U87, A431, PC3M-LN4, and 22Rv1). Results from U87 and 22Rv1 cells are shown in Image A. Specificity of the conjugate for the integrin receptor was confirmed by competition with either unlabeled RGD peptide or unlabeled RAD, non-specific peptide, in U87 cells (Image B). In addition, Images C and D confirm IRDye 800CW RGD maintains specificity to the target tissue in in vivo applications. Images of nude mice bearing two subcutaneously implanted tumors on the hips illustrate IRDye 800CW RGD localized to tumor tissue (Image C). A dose of unlabeled RGD (given intravenously via the tail vein) prior to IRDye 800CW RGD gave reduced signal in both tumors confirming specificity (Image D).

A
RGD Figure A
B
RGD Figure B
Cell Images

Figure: A) The On-Cell Western cell-based assay was used to evaluate binding affinity of IRDye 800CW RGD to U87 (glioblastoma) and 22Rv1 (prostate carcinoma) tumor cell lines. B) Binding of the IRDye 800CW RGD peptide was blocked by unlabeled RGD but not by a non-specific RAD peptide in U87 tumor cells. Nude mice bearing subcutaneous tumors, U87 (left hip) and A431(right hip), were imaged 24 hours post intravenous injection of IRDye 800CW RGD (1 nmole; C) or IRDye 800CW RGD (1 nmole) following a pre-injection 1 hour prior to an injection of unlabeled RGD peptide (100 nmoles; D) Images were captured on the Pearl Imager; 800nm signal is presented in pseudo-color overlaid on a white light image of the mouse. The images are normalized to the same look-up-table.

Advantages of NIR Optical Agents

  • High signal-to-noise ratio.
  • Low NIR autofluorescence from tissues, cells, and biological materials.
  • IRDye 800CW absorption/emission near 800 nm matches NIR absorption minima for bodily fluids and tissues, resulting in excellent tissue penetration.

IRDye 800CW in PBS

Click on the poster below to view/download the full-size PDF file..

RDG Poster

 

 

Ordering Information:

Part # DescriptionUnit/SizeDownloads
926-09889IRDye 800CW RGD Optical Probe
IRDye 800CW RGD Optical Probe from LI-COR Biosciences is a near-infrared labeled imaging agent specifically designed to target integrins. Integrins are cell surface heterodimeric glycoproteins important in cell adhesion and signal transduction. This receptor class is involved in tumor growth, tumor invasiveness, metastasis, tumor-induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis. Shipper: Dry Ice Storage: -20°C
15 nmoldescription
msds
pack insert
corner corner

Specifications

IRDye 800CW RGD: 15 nmol per tube

Specificity: Several cell lines have been evaluated with this optical agent including: A431, U87, 22Rv1, and PC3M-LN4.

IRDye 800CW

• Absorption maximum: 774 nm

• Emission maximum: 789 nm

   
corner corner

References

  1. Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of integrins. Med Res Rev. 1994;14:192–228.

  2. Achilefu S.  2004.  Lighting up tumors with receptor-specific optical molecular probes.  Technol Cancer Res Treat 3:393-409.

  3. Chen X, Conti PS, Moats RA.  2004.  In vivo near-infrared fluorescence imaging in integrin αvβ3 in brain tumor xenografts. Cancer Res  64:8009-8014.

   

 

 

 

 

 
 
 
Biotechnology
4647 Superior St Lincoln, NE 68504
Toll-Free: 800-645-4267
Email: biohelp@licor.com
Environmental
4421 Superior Street Lincoln, NE 68504
Toll-Free: 800-447-3576
Email: envsales@licor.com
© 2009 LI-COR Biosciences